Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
Completed
- Conditions
- Prostatic Hyperplasia
- Registration Number
- NCT00316732
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 173
Inclusion Criteria
- Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
- Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
- Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.
Exclusion criteria: None specified
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧Wakefield, United Kingdom